Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: ACADIA Pharmaceuticals Inc.

Market Cap 3.64B 3.14B 2.89B 2.71B 5.09B 344B 5.14B 34.15B 13.34B 169B 13.66B 13.38B 583B P/E Ratio 2026 *
54.9x
P/E Ratio 2027 * 29.6x
Enterprise Value 2.67B 2.31B 2.12B 1.99B 3.74B 253B 3.78B 25.08B 9.8B 124B 10.04B 9.82B 428B EV / Sales 2026 *
2.15x
EV / Sales 2027 * 1.69x
Free-Float
99.68%
Yield 2026 *
-
Yield 2027 * -
1 day-1.58%
1 week-4.10%
Current month-3.30%
1 month+1.23%
3 months-2.08%
6 months-21.85%
Current year-21.58%
1 week 20.92
Extreme 20.92
22.14
1 month 20.3
Extreme 20.3
22.14
Current year 19.89
Extreme 19.89
27.81
1 year 19.69
Extreme 19.69
28.35
3 years 13.4
Extreme 13.4
33.99
5 years 12.24
Extreme 12.24
33.99
10 years 12.24
Extreme 12.24
58.72
Manager TitleAgeSince
Chief Executive Officer 55 2024-09-19
Director of Finance/CFO 52 2021-09-09
Chief Tech/Sci/R&D Officer - 2025-08-03
Director TitleAgeSince
Director/Board Member 68 2008-04-30
Chairman 55 2016-06-09
Director/Board Member 73 2015-11-24
Date Insider Type Main position Quantity % Market Cap.
05-28Fiscal year

Director

41,529 0.0243%
05-28Fiscal year

Director

29,335 0.0171%
05-28Fiscal year

Director

41,529 0.0243%
Change 5-day change 1-year change 3-year change Capi.($)
-1.58%-4.10%-5.40%-12.98% 3.64B
-0.24%-0.26%-12.87%-12.97% 43.58B
-3.21%+3.90%+290.70%+531.11% 34.03B
-0.13%-4.48%+11.71%-17.64% 29.77B
-0.21%-0.89%+0.52%+32.76% 29.82B
-0.29%+9.47%+13.95%+21.93% 25.42B
+2.66%+7.09% - - 13.87B
-1.53%-1.65%+52.52%+106.95% 13.35B
-0.76%-3.23%+2.68%+2.24% 12.85B
-1.62%-2.70%+105.92%+76.90% 12.22B
Average -0.71%+1.62%+51.08%+80.92% 21.86B
Weighted average by Cap. -0.74%+1.95%+58.92%+101.94%

Financials

2026 *2027 *
Net sales 1.24B 1.07B 985M 924M 1.73B 117B 1.75B 11.64B 4.55B 57.44B 4.66B 4.56B 199B 1.39B 1.2B 1.1B 1.03B 1.94B 131B 1.96B 13.02B 5.09B 64.27B 5.21B 5.1B 222B
Net income 66.5M 57.32M 52.75M 49.49M 92.96M 6.28B 93.89M 624M 244M 3.08B 250M 244M 10.65B 131M 113M 104M 97.43M 183M 12.37B 185M 1.23B 480M 6.06B 491M 481M 20.97B
Net Debt -967M -833M -767M -719M -1.35B -91.37B -1.36B -9.07B -3.54B -44.74B -3.63B -3.55B -155B -1.29B -1.11B -1.03B -962M -1.81B -122B -1.83B -12.13B -4.74B -59.85B -4.85B -4.75B -207B
Logo ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.
Employees
797
Date Price Change Volume
26-06-16 20.94 $ -1.53% 140,621
26-06-15 21.26 $ +0.83% 1,209,891
26-06-12 21.09 $ -1.40% 753,938
26-06-11 21.39 $ +0.66% 945,147
26-06-10 21.25 $ -2.70% 1,231,797
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
21.26USD
Average target price
31.65USD
Spread / Average Target
+48.84%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ACAD Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!